tokens: Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post-menopausal women whose disease has progressed despite tamoxifen therapy : anastrozole ( ARIMIDEX , Zeneca ) , letrozole ( FEMARA , Novartis ) and vorozole ( RIVIZOR , Janssen ) .
folded_tokens: three new aromatase inhibitor have recently complete phase iii evaluation as treatment of metastatic breast cancer in post-menopausal woman whose disease have progress despite tamoxifen therapy : anastrozole ( ARIMIDEX , Zeneca ) , letrozole ( FEMARA , Novartis ) and vorozole ( rivizor , Janssen ) .